Annotation Detail

Information
Associated Genes
FOXP3
Associated Variants
FOXP3 EXPRESSION
FOXP3 EXPRESSION
Associated Disease
breast cancer
Source Database
CIViC Evidence
Description
1,097 patients with breast cancer were evaluated for FOXP3 expression by IHC. FOXP3 expression was found in 405 tumor samples and associated with improved OS in patients treated with anthracycline-based adjuvant chemotherapy (6 cycles of 'FEC100' aka epirubicin + cyclophosphamide + 5-fluorouracil) but not in patients treated with sequential anthracycline->taxane (3 cycles of FEC100 followed by 3 cycles of docetaxel). In-vitro experiments confirmed that FOXP3 expression enhance anthracycline efficacy. The in vitro data consisted of testing the sensitivity of various breast cancer cell lines to anthracyclines after treatment with valproic acid (which increases FOXP3 expression). The authors observed that, while valproic acid has no intrinsic cytotoxic effect on tumor cells, it enhanced the cytotoxic effect of epirubicin specifically in cell lines where FOXP3 expression was increased.
Variant Origin
N/A
Variant Origin
N/A
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/928
Gene URL
https://civic.genome.wustl.edu/links/genes/11587
Variant URL
https://civic.genome.wustl.edu/links/variants/394
Rating
4
Evidence Type
Predictive
Disease
Breast Cancer
Evidence Direction
Supports
Drug
Epirubicin
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
22431701
Drugs
Drug NameSensitivitySupported
EpirubicinSensitivitytrue